BELLEROPHON THERAPEUTICS INC (BLPH)

US0787713009 - Common Stock

0.1025  -0.28 (-73.39%)

After market: 0.114 +0.01 (+11.22%)

Fundamental Rating

2

Taking everything into account, BLPH scores 2 out of 10 in our fundamental rating. BLPH was compared to 588 industry peers in the Biotechnology industry. BLPH scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BLPH is valued expensive and it does not seem to be growing.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

BLPH had negative earnings in the past year.
In the past year BLPH has reported a negative cash flow from operations.
In the past 5 years BLPH reported 4 times negative net income.
In the past 5 years BLPH always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of BLPH (-110.28%) is worse than 81.59% of its industry peers.
BLPH has a Return On Equity of -220.54%. This is in the lower half of the industry: BLPH underperforms 74.63% of its industry peers.
Industry RankSector Rank
ROA -110.28%
ROE -220.54%
ROIC N/A
ROA(3y)-121.74%
ROA(5y)-90.23%
ROE(3y)-309.79%
ROE(5y)-245.24%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BLPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

5

2. Health

2.1 Basic Checks

BLPH has more shares outstanding than it did 1 year ago.
BLPH has more shares outstanding than it did 5 years ago.
BLPH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -34.54, we must say that BLPH is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of BLPH (-34.54) is worse than 94.86% of its industry peers.
BLPH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -34.54
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

BLPH has a Current Ratio of 2.00. This indicates that BLPH is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of BLPH (2.00) is worse than 81.92% of its industry peers.
BLPH has a Quick Ratio of 2.00. This indicates that BLPH is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of BLPH (2.00) is worse than 80.43% of its industry peers.
Industry RankSector Rank
Current Ratio 2
Quick Ratio 2

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 38.27% over the past year.
EPS 1Y (TTM)38.27%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q2.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 22.86% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y50.96%
EPS Next 2Y5.24%
EPS Next 3Y39.61%
EPS Next 5Y22.86%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BLPH. In the last year negative earnings were reported.
Also next year BLPH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as BLPH's earnings are expected to grow with 39.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.24%
EPS Next 3Y39.61%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BLPH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BELLEROPHON THERAPEUTICS INC

NASDAQ:BLPH (10/13/2023, 7:00:02 PM)

After market: 0.114 +0.01 (+11.22%)

0.1025

-0.28 (-73.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.25M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -110.28%
ROE -220.54%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2
Quick Ratio 2
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)38.27%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y50.96%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y